Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sasanlimab + SBRT for Cisplatin-ineligible MIBC
NCT05241340Phase 2Active, not recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Feb 2022
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sasanlimab in muscle-invasive bladder cancer (MIBC), sponsored by Houston Methodist Research Institute. Started Feb 2022; status: active, not recruiting.
02
Drugs
sasanlimab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05241340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241340.